GlassScriptPhysician profile
Charles A Harper
NPI 1689663999
$1,860.17
in general payments reported to CMS, 2019-2025
26 companies · $160 in 2025
The $160 reported for 2025 was less than what a typical Obstetrics provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $319 · 2020: $214 · 2021: $562 · 2022: $283 · 2023: $218 · 2024: $104 · 2025: $160.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $483.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $482.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $658.16 | 2019-2023 | |
| Avion Pharmaceuticals | $287.76 | 2019-2023 | Balcoltra |
| Exeltis, USA INC. | $171.60 | 2019-2023 | Slynd |
| Organon LLC | $97.78 | 2021-2024 | Nexplanon |
| Shield Therapeutics INC | $92.01 | 2023-2025 | Accrufer |
| Lupin INC. | $61.56 | 2020-2021 | |
| Evofem Biosciences, INC. | $60.28 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $56.09 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.38 | 2020-2025 | |
| Mylan Pharmaceuticals INC. | $42.29 | 2022 | |
| Mayne Pharma Commercial LLC | $38.69 | 2023 | |
| Novo Nordisk INC | $33.96 | 2025 | Rybelsus, Ozempic |
| Dexcom, INC. | $28.04 | 2025 | Dexcom G6 Transmitter |
| Biogen, INC. | $27.05 | 2025 | Zurzuvae |
| Hologic Sales and Service, LLC | $21.92 | 2025 | Fetal Fibronectin Enzyme Immunoassay |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coopersurgical, INC. | $21.01 | 2023 | Paragard T 380a |
| Therapeuticsmd, INC. | $17.53 | 2022 | |
| Exact Sciences Corporation | $15.79 | 2023 | Cologuard Collection Kit |
| Mission Pharmacal Company | $15.06 | 2020 | |
| Vertical Pharmaceuticals, LLC | $15.05 | 2019 | |
| Astellas Pharma US INC | $14.97 | 2023 | Veozah |
| Scynexis, INC. | $14.10 | 2022 | |
| Allergan, INC. | $11.56 | 2019 | |
| Daiichi Sankyo INC. | $11.53 | 2020 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Harper listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.